Position in EXEL
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$255,195
-$22,380 QoQ
Shares Held
5,950
-6.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 94.21848739495799.ToString("F0")%
Shared 0.ToString("F0")%
None 5.781512605042017.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Aptus Capital Advisors, LLC holds $15,216,864 across 16 Biotechnology names. EXEL ranks #8 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
14,644 | $6,539,131 | |
| 2 | OCUL |
Ocular Therapeutix, Inc
|
529,779 | $4,487,228 | |
| 3 | RPRX |
Royalty Pharma plc
|
21,335 | $1,023,439 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,264 | $976,616 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,513 | $500,606 | |
| 6 | MIST |
Milestone Pharmaceuticals Inc.
|
280,250 | $333,497 | |
| 7 | INCY |
Incyte Corp
|
2,794 | $262,971 | |
| 8 | EXEL |
Exelixis, Inc.
This page
|
5,950 | $255,195 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $255,195 | 5,950 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $277,575 | 6,333 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||